記憶障害(Memory Impairment):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Memory Impairment - Pipeline Review, H1 2015
◆商品コード:GMDHC6157IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、世界における記憶障害(Memory Impairment)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・記憶障害(Memory Impairment)の概要
・記憶障害(Memory Impairment)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・記憶障害(Memory Impairment)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・記憶障害(Memory Impairment)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・記憶障害(Memory Impairment)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Memory Impairment – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Memory Impairment – Pipeline Review, H1 2015’, provides an overview of the Memory Impairment’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Memory Impairment
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Memory Impairment pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Memory Impairment
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Memory Impairment Overview 8
Therapeutics Development 9
Pipeline Products for Memory Impairment – Overview 9
Pipeline Products for Memory Impairment – Comparative Analysis 10
Memory Impairment – Therapeutics under Development by Companies 11
Memory Impairment – Therapeutics under Investigation by Universities/Institutes 12
Memory Impairment – Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Memory Impairment – Products under Development by Companies 15
Memory Impairment – Products under Investigation by Universities/Institutes 17
Memory Impairment – Companies Involved in Therapeutics Development 18
Calico LLC 18
Dart NeuroScience LLC 19
M et P Pharma AG 20
Neuren Pharmaceuticals Limited 21
Omeros Corporation 22
Pharnext SAS 23
Sunovion Pharmaceuticals Inc. 24
Takeda Pharmaceutical Company Limited 25
Memory Impairment – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
2-PMPA – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AC-253 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Antisense Oligonucleotide to Inhibit microRNA for Neurology – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
dehydroevodiamine hydrochloride – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug for Memory Impairment – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HT-0712 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
HT-3951 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NNZ-2591 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
P7-C3A20 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pregnenolone succinate – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PXT-864 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
roflumilast – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule 1 to Inhibit GlyT-1 for Memory Impairment – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule 1 to Inhibit PDE4 for Memory Impairment – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule 2 to Inhibit Glyt-1 for Memory Impairment – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule 2 to Inhibit PDE4 for Memory Impairment – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Activate LPL for CNS and Metabolic Disorders – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecule to Inhibit MAO-B for Memory Impairment – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule to Target GPR83 for CNS and Immunological Disorders – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules to Activate Carbonic Anhydrase for Learning and Memory Impairment – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Activate NAMPT for Neurological Disorders – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Activate PKC for CNS and Oncology – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules to Antagonize GALR3 for Memory Impairment – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Stem Cell Therapy for Memory Impairment and Brain Diseases – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Memory Impairment – Recent Pipeline Updates 64
Memory Impairment – Dormant Projects 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

[List of Tables]
Number of Products under Development for Memory Impairment, H1 2015 9
Number of Products under Development for Memory Impairment - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Development by Companies, H1 2015 (Contd..1) 16
Products under Investigation by Universities/Institutes, H1 2015 17
Memory Impairment - Pipeline by Calico LLC, H1 2015 18
Memory Impairment - Pipeline by Dart NeuroScience LLC, H1 2015 19
Memory Impairment - Pipeline by M et P Pharma AG, H1 2015 20
Memory Impairment - Pipeline by Neuren Pharmaceuticals Limited, H1 2015 21
Memory Impairment - Pipeline by Omeros Corporation, H1 2015 22
Memory Impairment - Pipeline by Pharnext SAS, H1 2015 23
Memory Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 24
Memory Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Memory Impairment Therapeutics - Recent Pipeline Updates, H1 2015 64
Memory Impairment - Dormant Projects, H1 2015 67
Memory Impairment - Dormant Projects (Contd..1), H1 2015 68

[List of Figures]
Number of Products under Development for Memory Impairment, H1 2015 9
Number of Products under Development for Memory Impairment - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Top 10 Targets, H1 2015 27
Number of Products by Stage and Top 10 Targets, H1 2015 27
Number of Products by Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Top 10 Routes of Administration, H1 2015 31
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32
Number of Products by Top 10 Molecule Types, H1 2015 33
Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

【掲載企業】

Calico LLC
Dart NeuroScience LLC
M et P Pharma AG
Neuren Pharmaceuticals Limited
Omeros Corporation
Pharnext SAS
Sunovion Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited

★調査レポート[記憶障害(Memory Impairment):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6157IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[記憶障害(Memory Impairment):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆